Which has higher valuation and earnings, BDTX or APLM?

Black Diamond Therapeutics has higher revenue and earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Diamond Therapeutics $70M 1.49 $22.37M -$0.77 N/A Apollomics $8.50M 3.55 -$10.94M N/A N/A

Is BDTX or APLM more profitable?

Apollomics' return on equity of 0.00% beat Black Diamond Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -30.18% -23.91% Apollomics N/A N/A N/A

Do analysts prefer APLM or AIFC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, APLM or AIFC?

Apollomics has higher earnings, but lower revenue than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 3.55 -$10.94M N/A N/A ALT5 Sigma $24.84M 4.35 -$344.51M N/A N/A

Is APLM or AIFC more profitable?

Apollomics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Apollomics' return on equity of 0.00% beat ALT5 Sigma's return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A ALT5 Sigma -2,483.94% -68.25% -62.43%

Do analysts prefer CUE or APLM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, CUE or APLM?

Apollomics has lower revenue, but higher earnings than Cue Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cue Biopharma $27.47M 3.86 -$26.60M -$5.58 N/A Apollomics $8.50M 3.55 -$10.94M N/A N/A

Do analysts rate OTLK or APLM?

Oncobiologics currently has a consensus target price of $6.50, indicating a potential upside of 453.19%. Given Oncobiologics' stronger consensus rating and higher probable upside, equities analysts plainly believe Oncobiologics is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncobiologics 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, OTLK or APLM?

Apollomics has higher revenue and earnings than Oncobiologics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncobiologics $1.35M 121.90 -$62.42M -$1.17 N/A Apollomics $8.50M 3.55 -$10.94M N/A N/A

Is OTLK or APLM more profitable?

Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -291.28% Apollomics N/A N/A N/A

Do analysts prefer APLM or ENGN?

enGene has a consensus price target of $12.68, indicating a potential upside of 622.61%. Given enGene's stronger consensus rating and higher possible upside, analysts clearly believe enGene is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 enGene 1 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.21

Which has better valuation and earnings, APLM or ENGN?

Apollomics has higher revenue and earnings than enGene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 3.55 -$10.94M N/A N/A enGene N/A N/A -$117.30M -$2.25 N/A

Is APLM or ENGN more profitable?

Apollomics' return on equity of 0.00% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A enGene N/A -55.83% -45.74%

Apollomics (APLM) Competitors

$13.75 -0.56 (-3.92%)

As of 12:17 PM Eastern

Compare

APLM vs. BDTX, AIFC, CUE, OTLK, and ENGN

Should you buy Apollomics stock or one of its competitors? MarketBeat compares Apollomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Apollomics include Black Diamond Therapeutics (BDTX), ALT5 Sigma (AIFC), Cue Biopharma (CUE), Oncobiologics (OTLK), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry.

How does Apollomics compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Apollomics' return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
Apollomics	N/A	N/A	N/A

Black Diamond Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 450.96%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Black Diamond Therapeutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Black Diamond Therapeutics has higher revenue and earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.49	$22.37M	-$0.77	N/A
Apollomics	$8.50M	3.55	-$10.94M	N/A	N/A

Black Diamond Therapeutics has a beta of 3.22, indicating that its stock price is 222% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

In the previous week, Apollomics had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 2 mentions for Apollomics and 1 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.90 beat Apollomics' score of 1.44 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Black Diamond Therapeutics	Very Positive
Apollomics	Positive

Summary

Black Diamond Therapeutics beats Apollomics on 10 of the 14 factors compared between the two stocks.

How does Apollomics compare to ALT5 Sigma?

Apollomics (NASDAQ:APLM) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Apollomics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Apollomics' return on equity of 0.00% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Apollomics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market.

Apollomics has higher earnings, but lower revenue than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	3.55	-$10.94M	N/A	N/A
ALT5 Sigma	$24.84M	4.35	-$344.51M	N/A	N/A

In the previous week, ALT5 Sigma had 3 more articles in the media than Apollomics. MarketBeat recorded 5 mentions for ALT5 Sigma and 2 mentions for Apollomics. Apollomics' average media sentiment score of 1.44 beat ALT5 Sigma's score of 0.38 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Positive
ALT5 Sigma	Neutral

Summary

Apollomics beats ALT5 Sigma on 6 of the 11 factors compared between the two stocks.

How does Apollomics compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

In the previous week, Apollomics had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 2 mentions for Apollomics and 1 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 1.87 beat Apollomics' score of 1.44 indicating that Cue Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Cue Biopharma	Very Positive
Apollomics	Positive

Apollomics has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Apollomics' return on equity of 0.00% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Apollomics	N/A	N/A	N/A

Apollomics has lower revenue, but higher earnings than Cue Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	3.86	-$26.60M	-$5.58	N/A
Apollomics	$8.50M	3.55	-$10.94M	N/A	N/A

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cue Biopharma has a beta of 2.51, indicating that its share price is 151% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market.

Summary

Cue Biopharma beats Apollomics on 6 of the 11 factors compared between the two stocks.

How does Apollomics compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Apollomics has higher revenue and earnings than Oncobiologics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	121.90	-$62.42M	-$1.17	N/A
Apollomics	$8.50M	3.55	-$10.94M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
Apollomics	N/A	N/A	N/A

Oncobiologics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

In the previous week, Oncobiologics had 10 more articles in the media than Apollomics. MarketBeat recorded 12 mentions for Oncobiologics and 2 mentions for Apollomics. Apollomics' average media sentiment score of 1.44 beat Oncobiologics' score of 0.90 indicating that Apollomics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncobiologics	Positive
Apollomics	Positive

Oncobiologics currently has a consensus target price of $6.50, indicating a potential upside of 453.19%. Given Oncobiologics' stronger consensus rating and higher probable upside, equities analysts plainly believe Oncobiologics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Oncobiologics and Apollomics tied by winning 6 of the 12 factors compared between the two stocks.

How does Apollomics compare to enGene?

Apollomics (NASDAQ:APLM) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Apollomics' return on equity of 0.00% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
enGene	N/A	-55.83%	-45.74%

enGene has a consensus price target of $12.68, indicating a potential upside of 622.61%. Given enGene's stronger consensus rating and higher possible upside, analysts clearly believe enGene is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Apollomics has higher revenue and earnings than enGene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	3.55	-$10.94M	N/A	N/A
enGene	N/A	N/A	-$117.30M	-$2.25	N/A

In the previous week, enGene had 9 more articles in the media than Apollomics. MarketBeat recorded 11 mentions for enGene and 2 mentions for Apollomics. Apollomics' average media sentiment score of 1.44 beat enGene's score of 0.08 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Positive
enGene	Neutral

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 10.5% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Apollomics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, enGene has a beta of -0.29, meaning that its stock price is 129% less volatile than the broader market.

Summary

Apollomics and enGene tied by winning 6 of the 12 factors compared between the two stocks.

Get Apollomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLM vs. The Competition

Export

Metric	Apollomics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$30.19M	$3.40B	$6.50B	$12.37B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	N/A	20.08	24.01	24.71
Price / Sales	3.55	326.19	540.55	165.59
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-4.76	8.11	10.55	6.85
Net Income	-$10.94M	$23.89M	$3.56B	$337.45M
7 Day Performance	-1.30%	3.36%	1.54%	2.70%
1 Month Performance	-5.76%	1.34%	2.48%	4.60%
1 Year Performance	113.49%	46.46%	26.49%	32.81%

Apollomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLM Apollomics	1.6644 of 5 stars	$13.75 -3.9%	N/A	+114.7%	$30.19M	$8.50M	N/A	45	Positive News Short Interest Decrease Gap Down
BDTX Black Diamond Therapeutics	3.623 of 5 stars	$2.12 -2.8%	$10.00 +371.7%	-24.2%	$121.48M	$70M	N/A	90	Positive News
AIFC ALT5 Sigma	0.2909 of 5 stars	$0.83 +5.2%	N/A	-93.5%	$116.01M	$24.84M	N/A	170	Gap Up
CUE Cue Biopharma	0.3624 of 5 stars	$28.40 -0.8%	N/A	-95.5%	$115.02M	$27.47M	N/A	60	Positive News
OTLK Oncobiologics	3.7405 of 5 stars	$0.81 +0.1%	$4.50 +452.7%	-33.0%	$114.03M	$1.35M	N/A	20	Short Interest Increase Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLM) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apollomics (APLM) Competitors

APLM vs. BDTX, AIFC, CUE, OTLK, and ENGN

How does Apollomics compare to Black Diamond Therapeutics?

Summary

How does Apollomics compare to ALT5 Sigma?

Summary

How does Apollomics compare to Cue Biopharma?

Summary

How does Apollomics compare to Oncobiologics?

Summary

How does Apollomics compare to enGene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apollomics (APLM) Competitors

APLM vs. BDTX, AIFC, CUE, OTLK, and ENGN

How does Apollomics compare to Black Diamond Therapeutics?

Do insiders & institutionals hold more shares of BDTX or APLM?

Is BDTX or APLM more profitable?

Do analysts prefer BDTX or APLM?

Which has higher valuation and earnings, BDTX or APLM?

Which has more volatility & risk, BDTX or APLM?

Does the media prefer BDTX or APLM?

Summary

How does Apollomics compare to ALT5 Sigma?

Do analysts prefer APLM or AIFC?

Do insiders and institutionals hold more shares of APLM or AIFC?

Is APLM or AIFC more profitable?

Which has more volatility and risk, APLM or AIFC?

Which has higher valuation and earnings, APLM or AIFC?

Does the media favor APLM or AIFC?

Summary

How does Apollomics compare to Cue Biopharma?

Does the media prefer CUE or APLM?

Is CUE or APLM more profitable?

Which has better earnings & valuation, CUE or APLM?

Do insiders & institutionals have more ownership in CUE or APLM?

Do analysts prefer CUE or APLM?

Which has more volatility & risk, CUE or APLM?

Summary

How does Apollomics compare to Oncobiologics?

Which has better valuation & earnings, OTLK or APLM?

Is OTLK or APLM more profitable?

Which has more risk & volatility, OTLK or APLM?

Does the media prefer OTLK or APLM?

Do analysts rate OTLK or APLM?

Do insiders & institutionals have more ownership in OTLK or APLM?

Summary

How does Apollomics compare to enGene?

Is APLM or ENGN more profitable?

Do analysts prefer APLM or ENGN?

Which has better valuation and earnings, APLM or ENGN?

Does the media favor APLM or ENGN?

Do insiders & institutionals have more ownership in APLM or ENGN?

Which has more risk and volatility, APLM or ENGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools